Isoniazid for 9 months

ApprovedSmall molecule

NNational Taiwan University Hospital

Isoniazid for 9 months is one of 47 small molecule programs targeting Tuberculosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TuberculosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

TuberculosisPhase 3

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Isoniazid for 9 months

NNational Taiwan University Hospital

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Lovaza

AstraZeneca

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison

Completed·NNational Taiwan University Hospital·Phase 3·NCT00767975·2,384 enrolled

Tuberculosis1 trial

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT00023452·8,053 enrolled

Type 2 Diabetes1 trial

Latent Tuberculosis in Type 2 Diabetes

Active, not recruiting·TTaichung Veterans General Hospital·Phase 4·NCT06874725·552 enrolled

Randomized1 trial

Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan

Unknown status·NNational Taiwan University Hospital·Phase 3·NCT02208427·283 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Isoniazid for 9 months. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoniazid for 9 months compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoniazid for 9 months. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Taiwan University Hospital

Isoniazid for 9 months

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Tuberculosis1 trial

Type 2 Diabetes1 trial

Randomized1 trial

References

Drug Info

Quick Facts

Related News